We are live on
!
Find out more
Pictet Asset Management Portfolio holdings
AUM
$105B
1-Year Est. Return
38.07%
This Fund
S&P 500
This Quarter
Est. Return
-2.69%
1 Year Est. Return
+38.07%
3 Year Est. Return
+113.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$90B
AUM Growth
-$2.64B
(-2.9%)
Cap. Flow
+$2.07B
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
17.41%
Holding
2,101
New
60
Increased
1,058
Reduced
623
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$327M |
| 2 |
Broadcom
AVGO
|
+$315M |
| 3 |
Mastercard
MA
|
+$262M |
| 4 |
Intuit
INTU
|
+$226M |
| 5 |
Digital Realty Trust
DLR
|
+$149M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$187M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$169M |
| 3 |
WCN
Waste Connections
WCN
|
+$141M |
| 4 |
NextEra Energy
NEE
|
+$134M |
| 5 |
Cadence Design Systems
CDNS
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.36% |
| 2 | Industrials | 16.63% |
| 3 | Healthcare | 13.3% |
| 4 | Financials | 8.12% |
| 5 | Consumer Discretionary | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Lockheed Martin
LMT
$140B
| $4.09M | ﹤0.01% |
9,162
-18,910
| -67% | -$8.7M |
|
827
Arrowhead Research
ARWR
$12.3B
| $3.97M | ﹤0.01% |
288,030
+273,816
| +1,926% | +$4.98M |
|
828
Snap
SNAP
$8.79B
| $3.91M | ﹤0.01% |
448,685
-76,620
| -15% | -$799K |
|
829
United Airlines
UAL
$40.6B
| $3.86M | ﹤0.01% |
55,821
+34,193
| +158% | +$3.23M |
|
830
Beam Therapeutics
BEAM
$2.76B
| $3.85M | ﹤0.01% |
174,844
+166,466
| +1,987% | +$4.36M |
|
831
Ovintiv
OVV
$17.5B
| $3.85M | ﹤0.01% |
89,879
+189
| +0.2% | +$8.07K |
|
832
Samsara
IOT
$22.9B
| $3.84M | ﹤0.01% |
100,264
+12,230
| +14% | +$570K |
|
|
EXAS
833
DELISTED
Exact Sciences
EXAS
| $3.79M | ﹤0.01% |
87,461
+18,120
| +26% | +$918K |
|
834
Roivant Sciences
ROIV
$26.1B
| $3.77M | ﹤0.01% |
364,923
-562,547
| -61% | -$6.08M |
|
835
Open Text
OTEX
$5.8B
| $3.77M | ﹤0.01% |
149,285
-6,660
| -4% | -$183K |
|
836
Pan American Silver
PAAS
$22.1B
| $3.76M | ﹤0.01% |
145,778
-166,175
| -53% | -$3.98M |
|
837
FirstService
FSV
$6.24B
| $3.69M | ﹤0.01% |
22,238
-660
| -3% | -$116K |
|
838
EVgo
EVGO
$497M
| $3.67M | ﹤0.01% |
1,378,959
-377,959
| -22% | -$1.17M |
|
|
DVAX
839
DELISTED
Dynavax Technologies
DVAX
| $3.66M | ﹤0.01% |
268,806
+255,190
| +1,874% | +$3.38M |
|
840
Celestica
CLS
$42.8B
| $3.54M | ﹤0.01% |
44,879
+23,973
| +115% | +$2.54M |
|
841
Magna International
MGA
$18.6B
| $3.52M | ﹤0.01% |
103,704
-5,826
| -5% | -$224K |
|
842
Mercer International
MERC
$32.3M
| $3.52M | ﹤0.01% |
572,889
-158,388
| -22% | -$1.06M |
|
843
Bio-Rad Laboratories Class A
BIO
$9.68B
| $3.49M | ﹤0.01% |
14,332
+1,214
| +9% | +$365K |
|
844
Gildan
GIL
$10.6B
| $3.42M | ﹤0.01% |
77,279
-1,269
| -2% | -$63.1K |
|
845
Roku
ROKU
$22.5B
| $3.37M | ﹤0.01% |
47,825
+4,106
| +9% | +$329K |
|
846
Suzano
SUZ
$9.88B
| $3.35M | ﹤0.01% |
+361,092
| New | +$3.61M |
|
847
Descartes Systems
DSGX
$6.65B
| $3.35M | ﹤0.01% |
33,292
-24
| -0.1% | -$2.65K |
|
848
Sprott Physical Silver Trust
PSLV
$13.6B
| $3.31M | ﹤0.01% |
+285,444
| New | +$3.08M |
|
849
Iovance Biotherapeutics
IOVA
$3.05B
| $3.27M | ﹤0.01% |
920,461
+89,402
| +11% | +$461K |
|
850
Wynn Resorts
WYNN
$10.6B
| $3.25M | ﹤0.01% |
38,945
-1,648
| -4% | -$141K |
|
Similar funds
Pictet Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Pictet Asset Management held 2,101 positions worth $90B, down 2.9% from $92.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Pictet Asset Management's Q1 2025 filing shows 60 new, 1,058 increased, 623 reduced and 92 closed positions. Its largest new stake was Verona Pharma: 703,063 shares worth $44.6M. The largest sale was Intra-Cellular Therapies Inc., an estimated $187M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Industrials and Healthcare.
- Pictet Asset Management's largest Q1 2025 buy was Verona Pharma: 703,063 shares worth $44.6M.
- Pictet Asset Management added most to Synopsys in Q1 2025, an estimated $327M increase.
- Pictet Asset Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $187M.
- Pictet Asset Management fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q1 2025, selling an estimated $46.5M.
- Pictet Asset Management's ten largest holdings make up 17% of its $90B portfolio in Q1 2025.
- Pictet Asset Management opened 60 new positions and closed 92 in Q1 2025.
- Pictet Asset Management's portfolio value fell 2.9% quarter-over-quarter to $90B.
Based on Pictet Asset Management's 13F filing for Q1 2025, filed 5 May 2025.